Stay updated on Dara-CyBorD in Myeloma: Clinical Trial

Sign up to get notified when there's something new on the Dara-CyBorD in Myeloma: Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Dara-CyBorD in Myeloma: Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a potential update in the complete response plus very good partial response rate following 4 cycles of induction therapy of daratumumab in combination with cyclophosphamide, bortezomib, and dexamethasone for previously untreated and relapsed subjects with multiple myeloma.
    Difference
    0.1%
    Check dated 2024-06-06T14:19:21.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for subjects with multiple myeloma, specifying inclusion and exclusion criteria based on health conditions and prior treatments. Previously, this section had no information provided.
    Difference
    30%
    Check dated 2024-05-22T20:57:24.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T23:12:54.000Z thumbnail image

Stay in the know with updates to Dara-CyBorD in Myeloma: Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Dara-CyBorD in Myeloma: Clinical Trial page.